• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
StudyDesignSample sizeInterventionReason for exclusion
Major depressive disorder
Aguglia et al., 1993343RCT108Sertraline vs. fluoxetineHigh loss to follow-up; High differential loss to follow-up
Amini et al., 2005344RCT36Mirtazapine vs. fluoxetineNo ITT analysis
Bauer et al., 2009345Systematic review7,155Venlafaxine, SSRIsNo critical appraisal, no dual literature reviews
Benkert et al., 2006346RCT242Mirtazapine vs. venlafaxineHigh attrition; no baseline characteristics
Cookson et al., 2006347Pooled analysis2,656Duloxetine vs. fluoxetine, paroxetine & placeboNo systematic literature search
Davidson et al., 2002348Pooled analysis1,097Venlafaxine vs. fluoxetineNo systematic literature search
Eckert et al., 2006349Systematic review2,198Duloxetine, Fluoxetine, VenlafaxineNo critical appraisal
Feiger et al., 2003350Pooled analysis1,088Sertraline vs. fluoxetineNo systematic literature search
Flament et al., 2001351RCT286Sertraline vs. fluoxetineNo ITT analysis
Goldstein et al., 2004352RCT353Duloxetine vs. ParoxetineHigh loss to follow-up
Gorman et al., 2002353Meta-analysis1,321Escitalopram vs. citalopramNo systematic literature search
Grigoriadis et al., 2003354Observational201Citalopram vs. fluoxetineNo ITT analysis
Herrera-Guzmán, et al., 2009355RCT73Escitalopram, DuloxetinePoor randomization
Herrera-Guzmán 2010356RCT73Escitalopram, DuloxetinePoor randomization
Kennedy et al., 2006357Systematic review2,687Escitalopram, SSRINo critical appraisal, no systematic literature search
Kennedy et al., 2009358Systematic review4,549Escitalopram, SSRIsNo critical appraisal
Lapierre et al., 1987359RCT63Fluvoxamine vs. placeboNo ITT analysis
Llorca et al., 2005360Pooled analysis506Escitalopram vs. citalopramNo systematic literature search
March et al., 1990361RCT54Fluvoxamine vs. placeboNo ITT analysis
Papakostas et al., 2007362Systematic review988Trazodone & nefazodone vs. SSRIsNo quality appraisal
Papakostas et al., 2007363Pooled analysis1,672Bupropion vs. SSRIsNo systematic literature search
Papakostas et al., 2008364Pooled analysis2,890Bupropion vs. SSRIsNo systematic literature search
Papakostas et al., 2008365Systematic review1,904Mirtazapine, SSRIsno systematic literature search
Perahia et al., 2008199Pooled analysis667Duloxetine vs. venlafaxineNo systematic literature search
Shelton et al. 2005366Pooled analysis1,391Venlafaxine vs. Fluoxetine and paroxetienNo systematic literature search
Stahl et al., 2000367RCT323Citalopram vs. sertraline vs. PlaceboHigh loss to follow-up
Stahl et al., 2002368Pooled analysis1,622Venlafaxine fluoxetine paroxetine placeboNo systematic literature search
Thase et al., 2001369Pooled analysis2,117Venlafaxine vs. SSRI vs. placeboNo systematic literature search
Thase et al, 2005370Meta-analysis1,975Bupropion vs. SSRINo systematic literature search
Thase et al., 2006371RCT348Bupropion vs. venlafaxineHigh loss to follow-up
Thase et al., 201087Systematic review1,484Mirtazapine, SSRIsNo systematic literature search
Trkulja, 201027Systematic reviewNREscitalopram vs. citalopramNo dual literature review
Wade et al., 2003372RCT197Mirtazapine vs. paroxetineHigh loss to follow-up
MDD-Ped
DeVane et al., 1996373Meta-analysis61Fluoxetine vs. placeboNo systematic literature search
Emslie et al., 1997, 1998341, 374RCT96Fluoxetine vs. placeboLoss to follow-up differential > 15 percentage points
Emslie et al., 2002342RCT219Fluoxetine vs. placeboLoss to follow-up differential > 15 percentage points
Mayes et al., 2007375Pooled post hoc analysis315Fluoxetine vs. placeboNo systematic literature search
Generalized Anxiety Disorder
Bielski et al., 2005376RCT123Escitalopram vs. paroxetineHigh loss to follow-up
Kelsey et al., 2000377Pooled analysis2,000Venlafaxine vs. placeboNo systematic literature search
Stahl et al., 2007378Post hoc pooled analysis1,965Venlafaxine vs. placeboNo systematic literature search
Wan et al., 2006379Pooled analysis1,839Venlafaxine vs. placeboNo systematic literature search
OCD
Cox et al., 1993380Meta-analysisNot reportedClomipramine vs. fluoxetine vs. behavior therapyLack of information on included studies
Greist et al., 1995381Meta-analysis1530Clomipramine vs. fluoxetine vs. fluvoxamine vs. sertralineNo systematic literature search
Kobak et al., 1998382Meta-analysisNot reportedFluoxetine vs. fluvoxamine vs. paroxetine vs. sertralineIncluded uncontrolled trials; lack of information on included studies
Panic
Nair et al., 1996383RCT148Fluvoxamine vs. placeboHigh loss to follow-up
PTSD
Chung et al., 2004384Open-label trial113Mirtazapine vs. SertralineSignificant differences in patient characteristics at baseline
Davidson et al. 1998385Open-label trial15FluovoxamineOpen-label, high loss to follow-up
Davidson et al., 1998386Open-label trial17NefazodoneOpen-label, high loss to follow-up
De Boer et al., 1992387Open-label trial24FluovoxamineOpen-label, high loss to follow-up
Martenyi et al., 2002388, 389RCT301Fluoxetine vs. placeboHigh loss to follow-up
Smajkic et al., 2001390RCT40Sertraline vs. paroxetine vs. venlafaxineSmall sample size, no ITTanalysis
Tucker et al., 2001391RCT323Paroxetine vs. placeboHigh loss to follow-up
Social Anxiety Disorder
Allgulander et al., 2001392RCT96Paroxetine vs. placeboNo ITT analysis, lack of statistical comparisons
PMDD
Diegoli et al., 1998393RCT120Pyridoxine, alprazolam, fluoxetine, propanololImportant information about study methodology not reported
Carr et al., 2002394Systematic reviewNRfluoxetineNo critical appraisal of study quality; no description of review process
Subgroups
Ashman et al., 2009395RCT52SertralineNo ITT
Beasley et al., 1991396, 397 and Tollefson et al., 1994398Meta-analysis3,065Fluoxetine vs. placeboNo systematic literature search
Desmarais et al, 2009 399Systematic review2,203SSRI, SNRI, TamoxifenNo critical appraisal, no systematic literature search
Gülseren et al. 2005400RCT25Fluoxetine vs. paroxetineHigh rate of post-randomization exclusions
Pettinati et al., 2010401RCT170SertralineHigh attrition
Rajji et al., 2008402Systematic reviewNot reportedSSRI, SNRI, Placebono dual literature reviews
Roy-Byrne et al. 2000403RCT64Nefazodone vs. placeboHigh loss to follow-up
Soares et al., 2010404RCT607Desvenlafaxine, EscitalopramNo ITT
Weintraub et al., 2010405RCT130Sertraline, PlaceboHigh attrition
Adverse Events
Baldwin et al., 2007406Pooled analysisEscitalopram vs. placeboNo systematic literature search
Croft et al., 2002239RCT432Buprprion vs. placeboHigh loss to follow-up
Demyttenaere et al. 2005 407RCT85SSRIs vs. placeboNo ITT analysis
Ferguson et al., 2001408RCT72Nefazodone vs. sertralineSelection bias
Kennedy et al., 2000409Prospective cohort174Paroxetine vs. sertraline vs. venlafaxineNo ITT analysis; high loss to follow-up
Letizia et al., 1996410Systematic review3,828Fluvoxamine vs. TCA vs. placeboSearch strategy not reported; no critical appraisal of study quality
Thase et al., 2006371RCT348Bupropion vs. venlafaxineHigh loss to follow-up
Wernicke et al., 1997411Meta-analysis4,016Fluoxetine, placebo, TCANo systematic literature search
Wernicke, 2007412Pooled analysis14,627Duloxetine vs. placeboNo systematic literature search

From: Appendix C, Characteristics of excluded studies for poor quality

Cover of Drug Class Review: Second-Generation Antidepressants
Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report [Internet].
Gartlehner G, Hansen RA, Reichenpfader U, et al.
Portland (OR): Oregon Health & Science University; 2011 Mar.
Copyright © 2011 Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.